Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Gout Therapeutics Market

Gout Therapeutics Market Share

Report ID: GMI10280
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Gout Therapeutics Market Share

The gout therapeutics sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative gout therapies leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Smaller players are focusing on specific gout therapies to gain significant expertise and compete with established players.

Gout Therapeutics Market Companies

Some of the eminent market participants operating in the gout therapeutics industry include:

Astrazeneca Plc
Addex Therapeutics
Abbvie Inc.
Amgen Inc.
Boehringer Ingelheim International GmbH
GSK plc
Merck & Co., Inc.
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals, Inc.
Sun Pharmaceutical Industries Ltd.
Takeda Pharmaceutical Company Ltd.
Teva Pharmaceuticals Industries Ltd.
Teijin Limited
Zydus Lifesciences Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The gout therapeutics market size was valued at USD 2.6 billion in 2023 and is estimated to grow at 7.3% CAGR from 2024 to 2032, driven by the rising incidence of gout.

The non-steroidal anti-inflammatory drugs segment of the gout therapeutics is forecasted to reach USD 1.7 billion by 2032, as they offer quick onset of action, often providing significant pain relief

U.S. gout therapeutics market size is projected to reach USD 1.8 billion by 2032, owing to the robust healthcare infrastructure.

Abbvie Inc, Amgen Inc, Boehringer Ingelheim International GmbH, GSK plc, Merck & Co., Inc, Novartis AG, and Pfizer Inc. among others.